N790.F LIR Life Sciences Corp.
- Market cap
- EUR 1.92M
- P/E
- -
- P/B
- 54.02x
- ROE
- -5,634.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is N790.F undervalued?
Graham numberThe Graham number of LIR Life Sciences Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LIR Life Sciences Corp. fundamental analysis
No fundamental analysis for LIR Life Sciences Corp. yet.
LIR Life Sciences Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LIR Life Sciences Corp.
LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system through formulations of GLP-1 combination therapies for obesity and metabolic disorders. The company is based in Vancouver, Canada.
Full company profileLIR Life Sciences Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LIR Life Sciences Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -424K | -3.46M | -3.96M |
| EBITDA | -424K | -3.46M | -3.96M |
| Net Income | -424K | -3.90M | -3.96M |
| EPS | -0.02 | -0.14 | -0.14 |
| Balance Sheet | |||
| Total Assets | 121K | 837K | 310K |
| Total Liabilities | 203K | 180K | 239K |
| Shareholders' Equity | -82.1K | 656K | 70.2K |
| Cash & Short-term Investments | 121K | 597K | 201K |
| Cash Flow | |||
| Operating Cash Flow | -248K | -2.04M | -1.58M |
| Capital Expenditure | 0.00 | 105K | 0.00 |
| Free Cash Flow | -248K | -2.15M | -1.58M |
| Ratios | |||
| ROE | - | -594.0% | -5,634.8% |
| ROA | -350.5% | -465.9% | -1,277.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
LIR Life Sciences Corp. dividends
LIR Life Sciences Corp. has not paid dividends in the last 2 fiscal years.
Who owns LIR Life Sciences Corp.
- Insiders 1.02%
- Institutions 0.00%
- Public & others 98.98%
- Shares outstanding 28.7M
- Free float 25.6M
LIR Life Sciences Corp. company profile
- Company name
- LIR Life Sciences Corp.
- Ticker
- N790.F
- ISIN
- CA50206C1005
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- April
- Address
- 1505 West 2nd Avenue, Vancouver, BC, Canada, V6J 1H2
- Phone
- (888) 436 7772
- Website
- lirlifesciences.com
About LIR Life Sciences Corp.
LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system through formulations of GLP-1 combination therapies for obesity and metabolic disorders. The company is based in Vancouver, Canada.
LIR Life Sciences Corp. management
2- Dr. Edward Joseph Mills Ph.D.CEO & Director · born 1975
- Mr. Harpreet Nijjar C.M.A., CPACFO, Corporate Secretary & Director · born 1988